Skip to main content

Advertisement

SpringerLink
Log in

The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus

  • Lupus (S Keeling, Section Editor)
  • Published:
Current Treatment Options in Rheumatology Aims and scope Submit manuscript

Opinion statement

Purpose of review The use of patient-reported outcomes (PROs) is increasing in rheumatology and other chronic diseases, with growing evidence of its utility in complementing physical and biochemical assessments to guide management of complex conditions, such as systemic lupus erythematosus (SLE). This review describes currently utilized PROs and their use in SLE, and highlights areas of unmet need that require further attention.

Recent findings Existing PRO instruments, both generic and SLE-specific, assess a variety of health-related quality of life (HRQoL) and, to a lesser extent, non-HRQoL domains that are frequently reported health issues in SLE patients – although there remain other important aspects that are not routinely assessed, including the ability of patients to participate in social roles and relationships.

Summary PRO domains pertinent to SLE patients will continue to be identified and these areas of unmet needs will have to be addressed by novel and existing PRO instruments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Dawson J, et al. The routine use of patient reported outcome measures in healthcare settings. BMJ. 2010;340:c186.

    Article  PubMed  Google Scholar 

  2. Touma Z, Urowitz M, Gladman D. Outcome measures in systemic lupus erythematosus. Indian J Rheumatol. 2013;8(6):46–53.

    Article  Google Scholar 

  3. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–43.

    Article  CAS  PubMed  Google Scholar 

  4. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28(3):525–32.

    CAS  PubMed  Google Scholar 

  5. Touma Z, et al. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol. 2011;38(9):1898–905.

    Article  PubMed  Google Scholar 

  6. Nantes SG, et al., Comparison of the sensitivity to change of the 36-item short form health survey and the lupusqol using various definitions of minimal clinically important differences in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken), 2017. https://doi.org/10.1002/acr.2324.

  7. Pons-Estel GJ, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257.

    Article  PubMed  Google Scholar 

  8. Neville C, et al. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol. 2000;27(3):675–9.

    CAS  PubMed  Google Scholar 

  9. Yen JC, Neville C, Fortin PR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus. 1999;8(8):660–70.

    Article  CAS  PubMed  Google Scholar 

  10. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res. 2013;13:211.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Marshall S, Haywood K, Fitzpatrick R. Impact of patient-reported outcome measures on routine practice: a structured review. J Eval Clin Pract. 2006;12(5):559–68.

    Article  PubMed  Google Scholar 

  12. Santana MJ, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res. 2014;23(5):1505–13.

    Article  PubMed  Google Scholar 

  13. Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology. 2009;48(12):1533–6.

    Article  PubMed  Google Scholar 

  14. Wells G, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):260–5.

    Article  CAS  PubMed  Google Scholar 

  15. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Julian LJ, et al. Using the Center for Epidemiologic Studies Depression Scale to screen for depression in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(6):884–90.

    Article  Google Scholar 

  17. Mackie SL, et al. The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica. J Rheumatol, 2017;44(10):1515–1521. https://doi.org/10.3899/jrheum.161109

  18. Rasch LA, et al. Validating rheumatoid arthritis remission using the patients’ perspective: results from a special interest group at OMERACT 2016. J Rheumatol. 2017. https://doi.org/10.3899/jrheum.161111

  19. Administration, U.S.F.a.D. Guidance for industry: systemic lupus erythematosus: developing medical products for treatment. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063pdf. Accessed 15 Oct 2017

  20. Publications, D.o.H. Equity and excellence: Liberating the NHS. Presented to Parliament by the Secretary of State for Health by Command of Her Majesty. 2010. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213823/dh_117794.pdf. Accessed 15 Oct 2017.

  21. Leong KP, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76.

    Article  CAS  Google Scholar 

  22. Smolen JS, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol. 1999;26(2):504–7.

    CAS  PubMed  Google Scholar 

  23. Strand V, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999;26(2):490–7.

    CAS  PubMed  Google Scholar 

  24. van Tuyl LH, Boers M. Patient-reported outcomes in core domain sets for rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):705–12.

    Article  PubMed  Google Scholar 

  25. Tugwell P, Boers M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J Rheumatol. 1993;20(3):555–6.

    CAS  PubMed  Google Scholar 

  26. Boers M, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994;41:86–9.

    CAS  PubMed  Google Scholar 

  27. Kilic L, et al. The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: a systematic review of 250 articles. J Rheumatol. 2016;43(7):1300–5.

    Article  PubMed  Google Scholar 

  28. Pincus T, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35(2):201–5.

    PubMed  Google Scholar 

  29. Tunis SR, et al. Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets. J Rheumatol 2017. This study addresses important strategies to improve engagement throughout the process of developing core outcome sets and to promote their use and uptake. J Rheumatol. 2017;44(10):1551–1559. https://doi.org/10.3899/jrheum.161273

  30. Rycroft-Malone J, et al. Collaboration and co-production of knowledge in healthcare: opportunities and challenges. Int J Health Policy Manag. 2016;5(4):221–3.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Concannon TW, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med. 2012;27(8):985–91.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rader T, et al. Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences. J Rheumatol. 2014;41(2):206–15.

    Article  PubMed  Google Scholar 

  33. Mahieu M, Yount S, Ramsey-Goldman R. Patient-reported outcomes in systemic lupus erythematosus. Rheum Dis Clin North Am. 2016;42(2):253–63.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Cervera R, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore). 2003;82(5):299–308.

    Article  Google Scholar 

  35. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3(1):1–54.

    Article  CAS  PubMed  Google Scholar 

  36. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13(5):345–51.

    Article  CAS  PubMed  Google Scholar 

  37. Urowitz MB, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35(11):2152–8.

    Article  PubMed  Google Scholar 

  38. Bichile T, Petri M. Prevention and management of co-morbidities in SLE. La Presse Médicale. 2014;43(6):e187–95.

    Article  PubMed  Google Scholar 

  39. Strand V, et al. Endpoints: consensus recommendations from OMERACT IV. Lupus. 2000;9(5):322–7.

    Article  CAS  PubMed  Google Scholar 

  40. Cella D, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010;63(11):1179–94.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Robinson D Jr, et al. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res (Hoboken). 2010;62(2):266–73.

    Article  Google Scholar 

  42. Beckerman NL. Living with lupus: a qualitative report. Soc Work Health Care. 2011;50(4):330–43.

    Article  PubMed  Google Scholar 

  43. McElhone K, et al. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;19(14):1640–7.

    Article  CAS  PubMed  Google Scholar 

  44. Cleanthous S, et al. What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus. 2012;21(5):465–76.

    Article  CAS  PubMed  Google Scholar 

  45. Tench CM, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford). 2000;39(11):1249–54.

    Article  CAS  Google Scholar 

  46. Fatigue., A.H.C.o.S.L.E.R.C.f. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum. 2007;57(8):1348–57.

    Article  Google Scholar 

  47. McElhone K, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972–9.

    Article  PubMed  Google Scholar 

  48. Jolly M, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012;42(1):56–65.

    Article  PubMed  Google Scholar 

  49. Lai JS, et al. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38(4):672–9.

    Article  PubMed  Google Scholar 

  50. Strand V, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–44.

    Article  CAS  PubMed  Google Scholar 

  51. Petri MM, RS Martin, Hislop C, Scheinberg MA, Furie R, Effects of blisibimod, an inhibitor of B cell activating factor, on patient reported outcomes and disease activity in patients with systemic lupus erythematosus [abstract]. 2014.

  52. Holloway L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes. 2014;12:116–6.

  53. Petri MA, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50(9):2858–68.

    Article  CAS  PubMed  Google Scholar 

  54. Krupp LB, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.

    Article  CAS  PubMed  Google Scholar 

  55. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):455–68.

    Article  PubMed  Google Scholar 

  56. Gladman DD, et al. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus. 1996;5(3):190–5.

    Article  CAS  PubMed  Google Scholar 

  57. Danoff-Burg S, Friedberg F. Unmet needs of patients with systemic lupus erythematosus. Behav Med. 2009;35(1):5–13.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Gallop K, et al. Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient’s perspective. Lupus. 2012;21(9):934–43.

    Article  CAS  PubMed  Google Scholar 

  59. Mattsson M, et al. Uncertainty and opportunities in patients with established systemic lupus erythematosus: a qualitative study. Musculoskeletal Care. 2012;10(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  60. Touma Z, Urowitz MB. Chapter 61 - Systemic Glucocorticoids A2 - Tsokos. In: George C, editor. Systemic Lupus Erythematosus. Boston: Academic Press; 2016. p. 521–31.

    Chapter  Google Scholar 

  61. Jolly M, et al. Body image in patients with systemic lupus erythematosus. Int J Behav Med. 2012;19(2):157–64.

    Article  PubMed  Google Scholar 

  62. Shen B, et al. Body image disturbances have impact on the sexual problems in chinese systemic lupus erythematosus patients. J Immunol Res. 2015;2015:204513.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Monaghan SM, et al. Relationship between appearance and psychological distress in rheumatic diseases. Arthritis Rheum. 2007;57(2):303–9.

    Article  PubMed  Google Scholar 

  64. Littleton H, Radecki Breitkopf C, Berenson A. Body image and risky sexual behaviors: an investigation in a tri-ethnic sample. Body Image. 2005;2(2):193–8.

    Article  PubMed  Google Scholar 

  65. Lichtenthal WG, et al. Investment in body image among patients diagnosed with or at risk for malignant melanoma. Body Image. 2005;2(1):41–51.

    Article  PubMed  Google Scholar 

  66. Panopalis P, et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum. 2007;57(8):1453–60.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Brey RL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58(8):1214–20.

    Article  CAS  PubMed  Google Scholar 

  68. Al Rayes H, C Tani, Mosca M, Medina-Rosas J, Moustafa A, Lambiris P, Touma Z, What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2016. 68 (suppl 10). http://acrabstracts.org/abstract/what-is-the-prevalence-of-cognitive-impairment-in-lupus-and-which-instruments-are-used-to-measure-it-a-systematic-review-and-meta-analysis/Accessed 16 Oct 2017

  69. Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2017; https://doi.org/10.3899/jrheum.161125.

  70. Julian LJ, et al. Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012;64(3):448–54.

    Article  Google Scholar 

  71. Moustafa, A, Hassanein M, Eder L, Wither JE, Fung W, Lambiris P, Touma Z. Prevalence and metric of depression and anxiety in lupus: a systematic review and meta-analys [abstract]. Arthritis Rheumatol. 2016(68). http://acrabstracts.org/abstract/prevalence-and-metric-of-depression-and-anxiety-in-lupus-a-systematic-review-and-meta-analys/ Accessed 16 Oct 2017

  72. Utset TO, et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000058.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Al Dhanhani AM, et al. Work factors are associated with workplace activity limitations in systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2044–52.

    Article  Google Scholar 

  74. Al Dhanhani AM, et al. Job accommodations availability and utilization among people with lupus: an examination of workplace activity limitations and work context factors. Arthritis Care Res (Hoboken). 2015;67(11):1536–44.

    Article  Google Scholar 

  75. Beaton DE, et al. OMERACT filter evidence supporting the measurement of at-work productivity loss as an outcome measure in rheumatology research. J Rheumatol. 2016;43(1):214–22.

  76. Chen H, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health. 2008;11(2):231–9.

    Article  PubMed  Google Scholar 

  77. Reilly MC, et al. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010;49(4):812–9.

    Article  Google Scholar 

  78. Gordon C, et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford). 2013;52(12):2292–301.

    Article  Google Scholar 

  79. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.

    Article  CAS  PubMed  Google Scholar 

  80. Stoll T, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(8):1608–14.

    CAS  PubMed  Google Scholar 

  81. Hurst NP, et al. Validity of Euroqol—a generic health status instrument—in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol. 1994;33(7):655–62.

    Article  CAS  PubMed  Google Scholar 

  82. Hurst NP, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36(5):551–9.

    Article  CAS  PubMed  Google Scholar 

  83. Strand V, Chu AD. Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus. J Rheumatol. 2011;38(9):1821–3.

    Article  PubMed  Google Scholar 

  84. Devilliers H, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford). 2015;54(5):940–9.

    Article  Google Scholar 

  85. Kiani AN, et al. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(9):1651–7.

    Article  Google Scholar 

  86. Urowitz M, et al. Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(9):1374–9.

    Article  CAS  Google Scholar 

  87. Strand V, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12(9):677–86.

    Article  CAS  PubMed  Google Scholar 

  88. Wallace DJ, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Nordmark G, et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38(7):531–40.

    Article  CAS  PubMed  Google Scholar 

  90. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36(2):115–22.

    PubMed  Google Scholar 

  91. Hanly JG, et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(6):961–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Wallace DJ, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534–42.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Castelino M, et al. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford). 2013;52(4):684–96.

    Article  Google Scholar 

  94. McElhone K, et al. Sensitivity to change and minimal important differences of the lupusqol in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68(10):1505–13.

    Article  Google Scholar 

  95. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res. 2005;5(3):317–26.

    Article  PubMed  Google Scholar 

  96. Strand, V, Diehl A, Christensen J, Wajdula J, Sridharan S, Healey PJ, Improvements in health-related quality of life and fatigue following administration of an IL-6 monoclonal antibody (PF-04236921) in an enriched population of subjects with active SLE [abstract]. Arthritis Rheumatol. 2015 (67). http://acrabstracts.org/abstract/improvements-in-health-related-quality-of-life-and-fatigue-following-administration-of-an-il-6-monoclonal-antibody-pf-04236921-in-an-enriched-population-of-subjects-with-active-sle/ 2017 Accessed 16 Oct 2017

  97. Strand V, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53(3):502–11.

    Article  CAS  Google Scholar 

  98. Doward LC, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68(2):196–200.

    Article  CAS  PubMed  Google Scholar 

  99. Aggarwal R, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16.

    Article  PubMed  Google Scholar 

  100. Kuriya B, et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):181–5.

    Article  PubMed  Google Scholar 

  101. Panopalis P, et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology. 2005;44(6):751–5.

    Article  CAS  PubMed  Google Scholar 

  102. Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12(2):346–53.

    Article  PubMed  Google Scholar 

  103. Ow YL, et al. Domains of health-related quality of life important and relevant to multiethnic English-speaking Asian systemic lupus erythematosus patients: a focus group study. Arthritis Care Res (Hoboken). 2011;63(6):899–908.

    Article  Google Scholar 

  104. Kasturi S, et al. Validity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus Erythematosus. J Rheumatol. 2017;44(7):1024–31.

  105. Oude Voshaar MA, et al. Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis. PLoS One. 2014;9(3):e92367.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Fries JF, et al. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol. 2009;36(9):2061–6.

    Article  PubMed  Google Scholar 

  107. Stamm TA, et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum. 2007;57(7):1287–95.

    Article  PubMed  Google Scholar 

  108. Yilmaz-Oner S, et al. Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus. Clin Rheumatol. 2016;35(3):617–22.

    Article  PubMed  Google Scholar 

  109. Pamuk ON, et al. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients. Lupus. 2015;24(8):816–21.

    Article  CAS  PubMed  Google Scholar 

  110. Devilliers H, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012;51(10):1906–15.

    Article  Google Scholar 

  111. Jolly M, et al. LupusQoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol. 2010;37(9):1828–33.

    Article  PubMed  Google Scholar 

  112. Bourre-Tessier J, et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada. J Rheumatol. 2013;40(8):1327–33.

    Article  PubMed  Google Scholar 

  113. Clowse ME, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind placebo-controlled trials. Arthritis Rheumatol. 2017;69(2):362–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Jolly M, et al. Body image intervention to improve health outcomes in lupus: a pilot study. J Clin Rheumatol. 2014;20(8):403–10.

  115. Jolly M, et al. Spanish LupusPRO: cross-cultural validation study for lupus. Lupus. 2013;22(5):431–6.

    Article  CAS  PubMed  Google Scholar 

  116. Mok CC, et al. Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. Arthritis Care Res. 2015;67(2):297–304.

    Article  Google Scholar 

  117. Jolly M, et al. Development and validation of the lupus impact tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(10):1542–50.

    Article  Google Scholar 

  118. Toloza SM, Jolly M, Alarcon GS. Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues. Curr Rheumatol Rep. 2010;12(4):237–49.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Queen’s University, Kingston, Ontario, Canada

    Andrew Kwan MSc, MD

  2. Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto Lupus Clinic, EW, 1-412, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada

    Andrew Kwan MSc, MD & Zahi Touma MD, PhD, FACP, FACR

  3. Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA

    Vibeke Strand MD, MACR, FACP

Authors
  1. Andrew Kwan MSc, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibeke Strand MD, MACR, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahi Touma MD, PhD, FACP, FACR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahi Touma MD, PhD, FACP, FACR.

Ethics declarations

Conflict of Interest

Dr. Strand reports consulting fees from Abbvie, Amgen, Anthera, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, EMD Serono, Genentech/Roche, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB outside the submitted work.

Andrew Kwan declare that they have no conflict of interest. Dr. Touma reports consulting fees from GlaxoSmithKline, AstraZeneca, Merck Serono and Janssen Pharmaceuticals .outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lupus

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kwan, A., Strand, V. & Touma, Z. The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. Curr Treat Options in Rheum 3, 308–321 (2017). https://doi.org/10.1007/s40674-017-0079-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40674-017-0079-6

Keywords

Search

Navigation